Evidence map›Paper›PMID 35551285›Full record

ArticlePloS one2022

Exposure factors associated with SARS-CoV-2 seroprevalence during the first eight months of the COVID-19 pandemic in the Netherlands: A cross-sectional study.

Demi M E Pagen, Stephanie Brinkhues, Nicole H T M Dukers-Muijrers, Casper D J den Heijer, Noortje Bouwmeester-Vincken, Daniëlle A T Hanssen, Inge H M van Loo, Paul H M Savelkoul, Christian J P A Hoebe

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Demi M E PagenDepartment of Sexual Health, Infectious Diseases and Environmental Health, South Limburg Public Health Service, Heerlen, The Netherlands.ORCID 0000-0003-1475-5474
Stephanie BrinkhuesDepartment of Sexual Health, Infectious Diseases and Environmental Health, South Limburg Public Health Service, Heerlen, The Netherlands.
Nicole H T M Dukers-MuijrersDepartment of Sexual Health, Infectious Diseases and Environmental Health, South Limburg Public Health Service, Heerlen, The Netherlands.ORCID 0000-0003-4896-758X
Casper D J den HeijerDepartment of Sexual Health, Infectious Diseases and Environmental Health, South Limburg Public Health Service, Heerlen, The Netherlands.
Noortje Bouwmeester-VinckenDepartment of Infectious Diseases, North Limburg Public Health Service, Venlo, The Netherlands.
Daniëlle A T HanssenDepartment of Medical Microbiology, Maastricht University Medical Centre (MUMC+), Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.ORCID 0000-0003-2401-2703
Inge H M van LooDepartment of Medical Microbiology, Maastricht University Medical Centre (MUMC+), Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
Paul H M SavelkoulDepartment of Medical Microbiology, Maastricht University Medical Centre (MUMC+), Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
Christian J P A HoebeDepartment of Sexual Health, Infectious Diseases and Environmental Health, South Limburg Public Health Service, Heerlen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe availability of valid Severe Acute Respiratory Syndrome Coronvirus-2 (SARS-CoV-2) serological tests overcome the problem of underestimated cumulative Coronavirus Disease 2019 (COVID-19) cases during the first months of the pandemic in The Netherlands. The possibility to reliably determine the number of truly infected persons, enabled us to study initial drivers for exposure risk in the absence of routine testing. Numerous activities or circumstances can accelerate virus spread, here defined as exposure factors. Hence, we aimed to evaluate a wide variety of demographic, behavioural and social exposure factors associated with seropositivity during the first eight months of the pandemic in Limburg, The Netherlands.

methodsSARS-CoV-2 point-seroprevalence was determined cross-sectionally to indicate previous infection in a convenience sample of minimal 10,000 inhabitants of the study province. All adult (18+ years) inhabitants of the study province were eligible to register themselves for participation. Once the initial 10,000 registrations were reached, a reserve list was kept to ensure sufficient participants. Possible exposure factors were mapped by means of an extensive questionnaire. Associated exposure factors were determined using univariable and multivariable logistic regression models.

resultsSeropositivity was established in 19.5% (n = 1,948) of the 10,001 participants (on average 49 years old (SD = 15; range 18-90 years), majority women (n = 5,829; 58.3%). Exposure factors associated with seropositivity included current education, working in healthcare and not working from home, and being a member of three or four associations or clubs. Specifically for February-March 2020, visiting an après-ski bar during winter sports in Austria, travelling to Spain, celebrating carnival, and participating in a singing activity or ball sport were associated with seropositivity.

conclusionsOur results confirm that relevant COVID-19 exposure factors generally reflected circumstances where social distancing was impossible, and the number and duration of contacts was high, in particular for indoor activities.

Indexed as

COVID-19SARS-CoV-2AdultAntibodies, ViralCross-Sectional StudiesFemaleHumansMiddle AgedNetherlandsPandemicsSeroepidemiologic StudiesAntibodies, Viral

Identifiers

PMID35551285
PMCPMC9097988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.